Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

[1]  M. Williams,et al.  Treatment of glioblastoma multiforme with radiotherapy and concomitant and adjuvant temozolomide: translation of randomised controlled trial evidence into routine clinical practice. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[2]  Paul S Mischel,et al.  Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[3]  M. Schocke,et al.  ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma , 2011, Neuroradiology.

[4]  Jonathan R. Young,et al.  Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy , 2011, Current neurology and neuroscience reports.

[5]  R. Stupp,et al.  Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? , 2010, Future oncology.

[6]  K. Schmainda,et al.  Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter‐ and intrapatient comparisons , 2010, Magnetic resonance in medicine.

[7]  P. LaViolette,et al.  Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity , 2010, Journal of magnetic resonance imaging : JMRI.

[8]  Edward Ashton,et al.  Quantitative MR in multi‐center clinical trials , 2010, Journal of magnetic resonance imaging : JMRI.

[9]  T. Mikkelsen,et al.  Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker , 2010, Journal of Neuro-Oncology.

[10]  A. Sahgal,et al.  Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[11]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[12]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[14]  P. Wen,et al.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.

[15]  Timothy F Cloughesy,et al.  Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.

[16]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[17]  Andrew E. Sloan,et al.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.

[18]  Thomas L Chenevert,et al.  Diffusion imaging: insight to cell status and cytoarchitecture. , 2006, Neuroimaging clinics of North America.

[19]  M T Nieminen,et al.  Potential of diffusion imaging in brain tumors: a review , 2006, Acta radiologica.

[20]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Tom Mikkelsen,et al.  Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[22]  J. Uhm.  Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[23]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.